Hypertension and/or hyperlipidemia Circulatory System Hypertensive diseases
Conditions
Interventions
This is a 6 month multi-center, pragmatic, quasi-experimental controlled trial involving community pharmacies and primary care in Portugal. A primary care unit has expressed interest in this collabora
Sponsors
Associação Nacional das Farmácias
Agrupamento dos Centros de Saúde (ACeS) do Baixo Mondego
Eligibility
Sex/Gender
All
Age
18 Years to 110 Years
Inclusion criteria
Inclusion criteria: 1. Patients of selected USF 2. Age 18 years or older 3. On medication for hypertension and/or hyperlipidemia For technical reasons, intervention patients need to be holders of a NHS number, users of a mobile phone, registered in the NHS online portal Citizen Area, adherent to the National Association of Pharmacies (ANF) Pharmacy Loyalty Program Saúda®, with a Pharmacy Patient Medication Record.
Exclusion criteria
Exclusion criteria: Diabetic patients
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Blood pressure at 6 months (patients with hypertension) 2. Total cholesterol at 6 months (patients with hyperlipidemia) 3. Proportion of controlled patients at 6 months Collected using the following data sources: pharmacy dispensing software and/or primary care software (all available data points in pharmacy visits/primary care appointments) and patient telephone surveys (baseline, 3 and 6 months). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Other cardiovascular risk factors in hyperlipidemia patients 40-65 years old, collected using the pharmacy dispensing software and/or primary care software (all available data points in pharmacy visits/primary care appointments) and patient telephone surveys (baseline, 3 and 6 months) 2. Adherence and persistence, collected using pharmacy dispensing software and/or primary care software (all available data points in refill/prescription data) and Measure Treatment Adherence (MAT) Scale validated for European Portuguese via patient telephone surveys (baseline, 3 and 6 months) 3. Proportion of adherent patients, collected using pharmacy dispensing software and/or primary care software (all available data points in refill/prescription data) and Measure Treatment Adherence (MAT) Scale validated for European Portuguese via patient telephone surveys (baseline, 3 and 6 months) Exploratory outcomes: 1. Medication profile, measured using pharmacy dispensing software and/or primary care software (baseline and last available medication profile at 3 and 6 months) and patient telephone survey (baseline, 3 and 6 months) 2. Use of health care resources, collected using patient telephone survey at baseline and 6 months 3. Patient satisfaction with pharmacy, collected using patient telephone survey at baseline and 6 months 4. Risk factors and cardiovascular risk (SCORE) in individuals not on hypertension nor hyperlipidemia medication with at least one risk factor, using pharmacy dispensing software (following end of recruitment) 5. Fidelity assessed using pharmacy dispensing software (6 month data) and patient telephone survey (baseline, 3 and 6 months) 6. Applicability and transferability assessed using Wang’s framework at the end of study Quality of life, preferences and cost data collected for a separate economic evaluation study. These are not secondary nor exploratory outcomes but will be collected alongside this trial and treated as outcomes in a separate economic study. | — |
Countries
Portugal
Outcome results
None listed